Company ProfilePremium

Memphasys Ltd

Company Profile Analysis

Ticker: MEM.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Memphasys Ltd - Company showcase

Year Founded & Workforce

2006

28 Employees

Memphasys Ltd logo

Memphasys Ltd Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Memphasys Ltd Overview

Memphasys is a micro-cap Australian reproductive-biotechnology company. After almost two decades of separation-science R&D, it has narrowed its focus to a single commercial asset: the patented Felix™ System. Felix is a benchtop console with a single-use cartridge. It uses electrophoresis and size-exclusion membranes to isolate viable sperm in about six to seven minutes, without the centrifugation used in conventional density-gradient and swim-up preparation. The business model is a classic razor/razor-blade model. Consoles are placed in IVF laboratories, and every procedure uses a cartridge, at a company-targeted price of A$80–150. After CE Mark (Dec 2025), TGA (Feb 2026), MHRA, Vietnamese, Thai and Turkish registrations, Memphasys has signed 11 public commercial agreements covering 31+ countries. These carry A$4.2m+ in announced multi-year contracted minimums, anchored by an exclusive national agreement with Monash IVF Group. Revenue is still very small (A$274k in FY2026). The balance sheet is fragile, with a going-concern material uncertainty, so Memphasys is best characterised as an early commercial-stage, single-product medtech that is highly dependent on external funding.


Company's own description (paraphrased from the FY2026 Annual Report)

The FY2026 Directors' Report describes Memphasys as an Australian reproductive biotechnology company focused on commercialising its patented Felix™ System for assisted reproduction. During FY2026 its stated activities were: rolling out Felix through contracted distribution and direct sales; progressing regulatory approvals; scaling manufacturing while lowering cartridge cost to expand margins; and enforcing a disciplined cost structure. The report states that Felix is the company's sole commercial priority. RoXsta™ and other complementary fertility diagnostics are kept as longer-term pipeline options. Note 1 of the financial statements keeps a broader legacy description: development and manufacture of cell and protein separation devices and consumables for healthcare, veterinary and biotechnology markets.

Independent characterisation

Memphasys is a pre-scale, single-product medical-device company in the IVF laboratory consumables niche. It has three defining features:

  1. Technology. Felix replaces the two incumbent sperm-preparation methods, density gradient centrifugation (DGC) and swim-up (SU). These methods have changed little in roughly 40 years. They take about an hour and are linked to oxidative stress and sperm DNA damage. Felix's differentiation rests on speed (about 6–7 minutes), standardisation (it is automated, so results depend less on the operator), and gentleness (no centrifugation).

  2. Revenue model. Revenue comes from (a) console sales or placements, which are paid consoles in some deals, for example "200 cartridges + 6 paid consoles" in Thailand, and (b) recurring single-use cartridges, one per procedure. Management targets A$80–150 per cartridge and "60%+ gross margin potential at target COGS" (Sep 2026 presentation). FY2026 direct costs roughly equalled revenue (A$273.5k vs A$273.8k), so gross margin is currently close to zero.

  3. Go-to-market. Two channels: (i) direct sales to IVF groups (Monash IVF in Australia; UK clinics; CFA Italia), and (ii) exclusive in-country distributors with minimum purchase obligations (ITL for MENA and Turkey; TMSC in Vietnam; IVF Envimed in Thailand; TK Biotech in Poland; NOVIVITAE in the Nordics; INVIDO LAB in the Czech Republic, Slovakia and one further market; Andrology Center Coimbatore / Andro Diagnostics in India; Vitrolife subsidiaries in Japan, Canada and New Zealand).

Revenue mix

Revenue typeFY2026 (AUD)Share of revenueSource
Sale of Felix™ System (consoles and cartridges, recognised at a point in time)273,793100%FY2026 AR Note 5
Services / subscription / licensing00%FY2026 AR Note 5
Memo: grant income (R&D Tax Incentive), not revenue384,175—FY2026 AR Note 5
Memo: other income (gain on disposal, interest, misc.)48,977—FY2026 AR Note 5

The console/cartridge split is not publicly disclosed. Management says that recurring cartridge revenue is the strategic priority ("sole focus on annual recurring revenue (cartridge model)", April 2026 investor presentation).

Value-chain position

R&D: Conducted largely in partnership with the University of Newcastle (NSW) under Laureate Professor John Aitken (Scientific Director). Additional R&D was paused in FY2026.

Manufacturing: Outsourced to third-party manufacturers (FY2024 AR). The names of the contract manufacturers are not publicly disclosed. A cloud-based inventory and operations platform was implemented in the June 2026 quarter.

Regulatory and quality: Held in-house. The CE Mark under EU MDR is the regulatory "passport" used for reliance pathways in Australia, the UK, Qatar, India and elsewhere.

Distribution: Mixed direct and distributor model (see 2.2).

End user: IVF laboratory embryologists in fertility clinics.

Customer types and end-markets

Customer typeExamples (disclosed)End-market
Large corporate IVF networksMonash IVF Group (22 Australian clinics); CFA Italia (Naples)Human ART: IVF/ICSI
Public / state hospital IVF unitsHamad Medical Corporation (Qatar's largest IVF institution)Human ART
Independent private fertility clinicsFour UK IVF groups in commercial evaluation; Japanese KOL clinics (Kobe, Reproduction Clinic Osaka, Kiba Park)Human ART
Specialist IVF distributorsITL (MENA/Turkey), TMSC (Vietnam), IVF Envimed (Thailand), TK Biotech (Poland), NOVIVITAE (Nordics), INVIDO LAB (Central Europe), Vitrolife subsidiaries (Japan, Canada, NZ)Human ART
Animal breeding (pipeline, on hold)Klean Gene Pty Ltd (adviser)Livestock reproduction

Strategy

Stated strategy (paraphrased themes from the FY2026 AR, Mar 2026 quarterly and Sep 2026 presentation)

  1. Pure-play Felix focus. The 2025 AGM announced a deliberate repositioning towards commercialising Felix only. RoXsta, AI-Port and media were placed on hold.

  2. Contracted, recurring revenue. Prioritise agreements with minimum annual cartridge volumes. The model is console placement, then cartridge pull-through, then repeat orders. Management's suggested investor KPI chain is: active clinics, then cartridge utilisation, then repeat orders, then recognised revenue.

  3. Regulatory leverage. Use the EU MDR CE Mark as the anchor for reliance or abridged pathways (TGA, MHRA, Qatar, India CDSCO, Vietnam, Thailand, Turkey).

  4. Direct plus distributor ("go-direct") model. Sell directly to large IVF groups (Monash, CFA, HMC, UK groups). Use exclusive in-country partners with minimums elsewhere.

  5. Margin expansion. Scale cartridge manufacturing and reduce COGS towards a 60%+ gross margin at A$80–150 per cartridge.

  6. Cost discipline. Restructuring cut quarterly operating outflows by 71% between the Dec 2025 and Jun 2026 quarters. Target burn of about A$250k a month.

Initiatives announced in the last 24 months

DateInitiativeDetailStatus
Sep 2025ITL MENA/Turkey partnership5-year exclusive; 15+ countries; about 353 clinics; about 140k cycles a yearActive
Oct–Dec 2025RecapitalisationA$772.5k placement (Oct); rights issue and shortfall (Nov); A$579k placement (Dec); shares in lieu of fees and servicesCompleted
Nov 2025Pure-play repositioningAGM strategy resetImplemented
Dec 2025"Match-ready" pre-CE-Mark clinic programmePre-deployments, including a full-day Felix deployment at HMC in Doha; ESHRE/ASPIRE KOL engagementCompleted
H1 FY2026Operating restructureRealigned structure; lower annualised costs; capital moved to manufacturing and salesCompleted
Feb 2026Regulatory accelerationTGA lodgement leading to approval within weeks; MHRA registration processCompleted
Q4 FY2026Cloud inventory and operations platformDemand forecasting, manufacturing planning, lead trackingImplemented
Jun 2026Monash IVF national rollout12-month exclusive; 22 clinics after 3-month pilotIn progress
Jun 2026Manufacturing and inventory buildFunded mainly by the A$1.2m placementIn progress
Jun–Sep 2026Southeast Asia and wider Europe distributor networkVietnam, Thailand, Poland, Nordics, Central EuropeActivating
Sep 2026European commercial team"Newly established" to support distributorsEarly
ESG / sustainabilityNone announced——

Targets and guidance

TargetValueOutcome
2026 contracted sales goalA$2.0mExceeded: about A$3.0m by Jul 2026; A$4.2m+ announced minimums by Sep 2026
TGA approvalBy Apr 2026Achieved Feb 2026
Average monthly cash burnAbout A$250k after the Dec 2025 quarterJun 2026 quarter about A$140k a month (A$422k), helped by payment timing
Gross margin at target COGS60%+Not yet achieved (about 0.1% in FY2026)
Sep 2026 quarter salesExpected to be "significantly higher again" than Jun quarterReport due mid/late Oct 2026
Medium-term revenue or EBITDA targets——

Products & Services

Felix™ System (commercial; the only revenue-generating product)

AttributeDetailSource
DescriptionAutomated benchtop sperm-separation device for human ART (IVF/ICSI). Uses electrophoresis to drive charged, mature sperm through size-exclusion polymeric membranes, isolating viable cells without centrifugationCompany "About" text, 2026 releases
Components(1) Felix console (capital item); (2) single-use Felix cartridge (consumable, one per procedure); (3) proprietary membranes, including biocompatible PVA polymeric membranes (AU patent 2017254772, granted 14 Sep 2023)FY2024 Appendix 4E; Sep 2026 presentation
Processing timeAbout 6 minutes (Sep 2026 presentation); about 7 minutes (Osaka study); incumbent methods take about 1 hourSep 2026 presentation; FY2024 Appendix 4E
Pivotal clinical evidenceRegistered, multi-centre, blinded, randomised sibling-oocyte trial across 10 Monash IVF centres in 103 couples. Primary endpoint, embryo utilisation rate: Felix 58.8% vs DGC 49.1% (p=0.022). Non-inferior to swim-up. 100% of clinicians preferred Felix to DGC. Results announced 24 Mar 2025 and presented at FSANZ on 9 Aug 2026Sep 2026 presentation; FSANZ release summary
Supporting evidenceOsaka (2024): blastocyst rate 58.4% vs 52.9%; good-quality blastocysts 35.7% vs 26.1%; embryo utilisation 58.0% vs 54.3% vs DGC+SU. Coimbatore (2023): 33 couples, 40 frozen transfers, 47.5% clinical pregnancy rate, 27.5% live-birth rate in a high-DNA-fragmentation cohortFY2024 Appendix 4E
Regulatory statusCE Mark under EU MDR (Dec 2025); TGA/ARTG (Feb 2026); UK MHRA registration (2026); Vietnam registration (Aug 2026); Turkey ÜTS registration (Aug/Sep 2026); Thai FDA approval (by Sep 2026). Japan, Canada and NZ were treated as early-access markets with no pre-sale clearance required. India CDSCO pending. Company counts 6 regulatory clearances/registrationsReleases Dec 2025–Sep 2026; Sep 2026 presentation
Target customerIVF laboratories: corporate networks, hospital units, independent clinics—
Launch / latest versionCommercial sales in Japan from 2022–23. The "post-launch enhancement" version is capitalised as a separate intangible (A$1.28m net book value at 30 Jun 2026)FY2026 AR Note 18
Pricing modelConsole sale or placement plus per-procedure cartridge. Company target A$80–150 per cartridge. Implied contract pricing: CFA Italia initial order 500 cartridges for A$62,500 (A$125 each); ITL about A$390k minimum for an initial 6,000-cartridge 5-year minimum (about A$65 each, distributor price, derived)Sep 2026 presentation; ASX 22 Dec 2025; Jun 2026 quarterly
Target economics"60%+" gross margin potential at target COGS. FY2026 actual gross margin about 0.1% (derived: revenue A$273,793 less direct costs A$273,488)Sep 2026 presentation; FY2026 AR
Addressable market (company estimate)About A$630m for Felix (FY2024 AR, citing Allied Market Research)FY2024 Appendix 4E
IP14+ granted patents in the US and AustraliaSep 2026 presentation
Flagship accountsMonash IVF Group (AU); Hamad Medical Corporation (Qatar), which has ordered a second console; CFA Italia; Japanese KOL clinics—

RoXsta™ (Rapid Oxidative Stress Assay), pipeline, scaled back

AttributeDetail
DescriptionPoint-of-care in-vitro diagnostic with single-use cartridges. A five-minute test of antioxidant capacity in semen, blood, follicular fluid or urine, used as a proxy for oxidative stress
ApplicationsMale infertility, pre-eclampsia/placental failure research, livestock reproduction (bovine), and potentially sports medicine and food safety
DevelopmentCo-developed with the University of Newcastle. An external product-development firm was contracted for the next iteration (FY2024). Small cartridge batch planned for early FY2025
IPAU provisional application 2023904171, "Methods and devices for measuring antioxidant levels in biological samples," filed 21 Dec 2023
SpendA$989,363 of research-phase spend in FY2024 (FY2023: A$646,791)
StatusScaled back in FY2026 in favour of Felix and kept as a longer-term pipeline option (FY2026 AR)
Pricing / launchNot publicly disclosed / not launched

AI-Port (animal semen transport), pipeline, on hold

Ambient-temperature (22–25°C) livestock semen preservation for up to seven days, avoiding cryopreservation. Two field trials have been completed. Further work depends on funding and partners within the "Memphasys Animal Breeding Solutions" project. The related research line, "new long-life sperm storage media (animal)," absorbed A$663,723 in FY2024 (FY2023: A$528,893). Status: paused (FY2026 AR risk factor 2).

IVF and cryopreservation media, research stage, on hold

Novel cryoprotectant media were developed with the University of Newcastle. The company reported that adding vitamin C restored sperm vitality and DNA integrity after thawing, and that commercial cryoprotectant destroyed about 50% of antioxidant activity (published in Antioxidants, 2024). Not commercialised.

Discontinued and divested products

ProductStatusDateSource
Samson (rapid equine pregnancy prediction assay)Discontinued (A$293,610 written to P&L in FY2023)FY2023FY2024 Appendix 4E
SemPort (semen transport system)Listed in historical pipeline; no current activity disclosed—Third-party profile
Precast electrophoresis gels (iGels, NuBlu, nUView)Divested with NuSep Inc. to Dycent BiotechApr 2017MarketScreener
ProteoIQ proteomics software (BioInquire)Legacy; status not disclosedc.2012ASX release, Oct 2012
PrIME Biologics (90% owned)Legacy; status not disclosedc.2012ASX release, Oct 2012

Financial Narrative

All figures are in AUD thousands (A$k) unless the row label says otherwise. FY2024 P&L figures follow the restated series in the FY2026 Remuneration Report unless marked "orig." Balance-sheet and cash-flow figures for FY2023–FY2024 come from the FY2024 Appendix 4E as originally reported. FY2025–FY2026 figures come from the audited FY2026 financial statements. FY2022 balance-sheet and cash-flow detail was not captured in the sources reviewed (blank cells).

Income statement

Sources: FY2026 AR P&L and Remuneration Report five-year table; FY2024 Appendix 4E for the FY2023–FY2024 line items. Discrepancies: (1) The FY2026 Appendix 4E gives "Underlying EBITDA" of -A$3,175k for FY2026 and -A$3,793k for FY2025. The Remuneration Report gives EBITDA of -A$3,094.9k and -A$3,801.5k. The difference reflects inclusion or exclusion of other income. (2) FY2024 EPS was originally -A$0.0019 and is -A$0.0023 restated.

Margins and growth (derived)

Revenue CAGR FY2022–FY2026 (4 years): 78.2% a year (derived: (273.8/27.1)^(1/4) − 1). The base is too small for this to be economically meaningful. Margins in the thousands of percent show that revenue is still immaterial relative to the cost base.

Balance sheet

Sources: FY2024 Appendix 4E; FY2026 AR. FY2022 cash and equity are taken from the FY2023 opening balances. Net debt = interest-bearing liabilities less cash (derived). Share-count anomaly: weighted-average shares are reported as 2,310.5m (FY2024) and 3,354.3m (FY2025), yet the closing count is 1,382.7m at 30 Jun 2024 and 1,983.6m at 30 Jun 2025. These figures do not reconcile in the filings reviewed and should be treated with caution.

Cash flow

Derived: FCF = OCF − capex (including capitalised development and cleanroom payments). Net borrowings combine third-party and related-party loan receipts less repayments.

Ratios (derived)

ROE uses average equity, with restated FY2024 equity where available. ROIC is not meaningful with negative NOPAT and is left blank. Net debt/EBITDA is negative because EBITDA is negative, which means the ratio cannot be interpreted conventionally. Cash conversion cycle: not meaningful. Derived FY2026 indicators: receivables of A$163k against revenue of A$274k (about 217 days of sales); trade payables rose from A$126k to A$1,381k, implying stretched supplier terms.

Trend commentary

Revenue inflection, from a near-zero base. Revenue was essentially nil for four years. It was A$27k in FY2022 and A$3.7k in FY2025, and came from Japanese early-access sales through Vitrolife. In FY2026 it reached A$273.8k, with 96% earned in the second half: 1H FY2026 A$12.4k, March quarter about A$112k, June quarter about A$150k (Jun 2026 quarterly). The driver was the regulatory unlock. CE Mark (Dec 2025) and TGA (Feb 2026) activated distributor minimums, with ITL ordering 1,800 cartridges, and led to initial orders from CFA Italia, UK trial clinics and Monash IVF. Management also disclosed "contracted FY26 sales of A$3m," later "A$4.2m+ minimum contracted sales publicly announced" (Sep 2026). These are multi-year minimum commitments, not recognised revenue, and investors should not treat them as an annual run-rate.

Gross margin has not yet emerged. FY2026 direct costs of A$273.5k matched revenue almost exactly. Possible reasons include early-volume manufacturing cost, console sales at or near cost, and inventory set-up. Management's 60%+ target therefore depends entirely on cutting cartridge COGS at scale. This is flagged as a key business risk ("Manufacturing costs," FY2026 AR risk 16).

Losses are narrowing because the cost base is shrinking, not because the business is scaling. Net loss fell 19% to A$4.10m. The drivers were lower R&D (down A$315k as RoXsta was scaled back), lower finance costs (down A$202k after third-party loans were repaid), and the absence of the FY2025 A$896k impairment. These savings were partly offset by much higher compliance, registry, accounting and legal costs (up A$448k to A$779k) and director expenses (up A$110k). Quarterly operating cash outflows fell 71%, from A$1.441m (Dec 2025 quarter) to A$831k (Mar 2026) and then A$422k (Jun 2026). Management guided to an average burn of about A$250k a month after the December quarter (1H FY2026 report).

The balance sheet depends on equity issuance and one lender. The company has raised A$3.4–4.0m of gross equity every year from FY2023 to FY2026, about A$14.8m in total. That broadly matches cumulative free-cash outflow. Shares on issue grew about 2.2x from 1,382.7m (Jun 2024) to 3,087.2m (Jun 2026), and 779m options are outstanding. The only interest-bearing debt is the A$4.24m (carrying value) Peters Investments convertible note. It is classified as current and has been extended repeatedly, most recently to 30 Jun 2027. Working capital is negative at -A$4.81m. Net assets of A$4.21m are less than the A$8.80m of Felix intangibles, so net tangible assets are negative (about -A$4.58m, derived). The auditor (BDO) included a material-uncertainty-related-to-going-concern paragraph for FY2026.

Intangibles are a valuation judgement. The Felix intangible (cost A$19.4m, less A$7.7m of R&D grants offset, less amortisation and impairment) is amortised over 20 years, which is long for a medical device. Its carrying value is supported by an impairment review that cites contracts and approvals rather than a disclosed discounted-cash-flow model.

Restatement note

The FY2026 Remuneration Report labels FY2024 as "Restated." It shows a FY2024 loss of A$5,371,322 against A$4,442,021 originally reported. The A$929,301 difference exactly equals the FY2024 grant income originally booked to P&L. Opening equity at 1 Jul 2024 was likewise reduced from A$6,837,755 to A$5,908,454 (a difference of A$929,301). The most likely explanation (an inference, not confirmed in the text reviewed) is that the R&D Tax Incentive was reclassified against capitalised development costs, consistent with the FY2026 policy note 3(i). Readers should use the restated FY2024 series for comparability.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentContentsProducts / servicesStatus

Reproductive Technologies

Felix™ System (human sperm separation); Felix membranes; RoXsta™ (oxidative-stress assay); AI-Port (animal semen transport); IVF/cryopreservation media; legacy separation IP

Consoles; single-use cartridges; pipeline diagnostics

Felix is commercial. All other projects are paused or on hold

Results by Segment and Segment Margins & Growth (%)

MetricFY2022FY2023FY2024FY2025FY2026

Segment revenue (AUD K)

27.115.460.03.7273.8

Segment revenue YoY growth (%)

—-43.4290.3-93.87,300.0

Segment pre-tax loss (AUD K)

-2,082.0-3,402.6-5,371.3-5,039.1-4,103.4

Segment EBIT (AUD K)

-2,249.9-2,992.5-4,970.1-4,467.8-3,719.6

Contribution to group revenue (%)

100100100100100

Function Details

FunctionLead (FY2026/27)Notes

Board / strategy

David Tasker (Chair)

No CEO since 31 Dec 2025

Commercialisation Committee

Marjan Mikel (Chair)

Paid strategic consultancy through Mikel Enterprises

Clinical engagement & growth

A/Prof Hassan Bakos

Formerly Director of Operations

Scientific

Laureate Prof John Aitken

Ceased to be KMP from 1 Jul 2026

ANZ key accounts

Dr Tony Poulton

Appointed in the Jun 2026 quarter for the Monash rollout

European commercial team

"Newly established" (Sep 2026)

Head not named in the sources reviewed

Finance / company secretarial

Stefan Ross (Co. Sec., Vistra)

Director of Finance Pablo Neyertz resigned 14 Nov 2025. Current CFO: not publicly disclosed

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Revenue (AUD K)

27.115.460.03.7273.8

Direct costs (AUD K)

—6.258.439.3273.5

Gross profit (AUD K)

—9.21.6-35.60.3

Grant income, R&D Tax Incentive (AUD K)

—588.0929.3523.2384.2

R&D expense through P&L (AUD K)

—1,469.32,138.61,294.5979.7

Employee benefits expense (AUD K)

—221.2852.7888.5930.0

Compliance, audit, tax and legal (AUD K)

—263.3332.0330.5778.6

Depreciation and amortisation (AUD K)

—619.4717.0666.3593.0

Impairment of intangibles (AUD K)

—00896.40

EBITDA (AUD K)

-2,126.7-2,379.7-4,257.7-3,801.5-3,094.9

Operating income / EBIT (AUD K)

-2,249.9-2,992.5-4,970.1-4,467.8-3,719.6

Finance costs (AUD K)

—428.2417.1585.4383.8

Pre-tax income (AUD K)

-2,082.0-3,402.6-5,371.3-5,039.1-4,103.4

Income tax (AUD K)

00000

Net income (AUD K)

-2,082.0-3,402.6-5,371.3-5,039.1-4,103.4

Net income as originally reported (AUD K)

-2,082.0-3,402.6-4,442.0-5,039.1-4,103.4

EPS basic (AUD)

-0.0027-0.0018-0.0023-0.0015-0.0016

EPS diluted (AUD)

-0.0027-0.0018-0.0023-0.0015-0.0016

Dividends per share (AUD)

00000

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Gross margin (%)

—60.02.7-961.90.1

EBITDA margin (%)

-7,834-15,482-7,096-102,743-1,130

Operating (EBIT) margin (%)

-8,288-19,469-8,284-120,751-1,359

Net margin (%)

-7,669-22,137-8,952-136,192-1,499

Revenue YoY growth (%)

—-43.4290.3-93.87,300.0

Balance Sheet and Share Count (millions)

MetricFY2022FY2023FY2024FY2025FY2026

Cash and equivalents (AUD K)

269.1637.8277.8298.31,178.5

Inventories (AUD K)

—130.8164.858.8165.7

R&D Tax Incentive receivable (AUD K)

———900.9384.2

Total current assets (AUD K)

—2,248.71,618.61,333.32,204.3

Intangible assets, Felix (AUD K)

—10,294.710,089.89,298.08,795.6

Goodwill (AUD K)

—0000

Total assets (AUD K)

—14,667.812,430.111,211.811,235.9

Short-term interest-bearing debt (AUD K)

—4,469.44,363.24,866.54,244.1

Long-term interest-bearing debt (AUD K)

—0000

Lease liabilities, total (AUD K)

—1,825.4396.0335.90

ATO / other statutory liabilities (AUD K)

—47.670.81,162.51,062.5

Total current liabilities (AUD K)

—5,567.35,254.16,591.57,019.0

Total liabilities (AUD K)

—7,283.25,592.46,870.17,023.2

Net debt excl. leases (AUD K)

—3,831.64,085.44,568.23,065.6

Total equity (AUD K)

7,646.57,384.76,837.84,341.64,212.7

Total equity, FY2024 restated (AUD K)

——5,908.5——

Working capital (AUD K)

—-3,318.6-3,635.5-5,258.2-4,814.7

Issued capital (AUD K)

50,340.953,417.857,280.360,613.364,511.2

Accumulated losses (AUD K)

-42,770.6-46,173.2-50,430.1-56,274.1-60,377.5

Shares on issue at year end (millions)

——1,382.71,983.63,087.2

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Receipts from customers (AUD K)

—15.460.03.7118.1

Government grant receipts (AUD K)

—1,504.01,315.11,119.0900.9

Operating cash flow (AUD K)

—-1,406.7-3,231.4-2,401.3-2,490.5

Capex incl. capitalised development (AUD K)

—1,976.7715.6819.73.4

Free cash flow (AUD K)

—-3,383.4-3,947.0-3,221.0-2,493.9

Equity issued, gross (AUD K)

—3,360.43,721.03,730.13,964.4

Net borrowings (AUD K)

—774.0289.5-19.7-479.3

Net financing cash flow (AUD K)

—3,752.13,539.63,253.13,374.1

Dividends paid (AUD K)

00000

Buybacks (AUD K)

00000

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2023FY2024FY2025FY2026

ROE (%)

-45.3-80.8-98.3-95.9

ROA (%)

—-39.6-42.6-36.6

Current ratio (x)

0.400.310.200.31

Debt / equity (x)

0.610.641.121.01

Net debt / EBITDA (x)

-1.61-0.96-1.20-0.99

Interest coverage, EBIT / finance costs (x)

-7.0-11.9-7.6-9.7

Asset turnover (x)

—0.0040.00030.024

Revenue by Region

MetricFY2024FY2025FY2026

Total revenue (AUD K)

60.03.7273.8

Revenue, Southeast Asia (AUD K)

——0

Revenue by Region (Quarterly)

Metric1H FY2026Q3 FY2026Q4 FY2026

Revenue (AUD K)

12.4112.0150.0

Region Overview

RegionStatusContracted minimum / volumes disclosedGrowth assessment

MENA (Qatar, UAE, Iraq, Kuwait, plus 15+ countries)

Fastest early adopter. ITL orders of 1,800 cartridges (72% of the 2,500 annual minimum) within two quarters of CE Mark. HMC ordered a second console

About A$390k minimum over 5 years

Fastest-growing. Driven by CE-Mark reliance, distributor minimums and HMC reference

Australia

Monash IVF 12-month exclusive national agreement; 2-site, 3-month rollout leading to 22 clinics

Terms confidential

High potential. Monash performed 12,085 stimulated cycles in 2025, about 21% of the national market

Europe – Italy

CFA Italia 5-year agreement; initial 500-cartridge order; repeat orders

About A$925k minimum; 7,500 cartridges, front-loaded

Growing

UK

Four IVF groups in paid commercial evaluation after MHRA registration

Not contracted

Early

Europe – Poland

TK Biotech exclusive (5 Aug 2026); first minimum order expected in the Dec 2026 quarter

Not captured

Early

Europe – Nordics (5 markets)

NOVIVITAE exclusive (1 Sep 2026)

€526,500

Early

Europe – Czech Republic, Slovakia and one further market

INVIDO LAB, 3-year exclusive (18 Sep 2026)

About A$674k (at €1 = A$1.62)

Early

Turkey

ÜTS registration; first sale of 100 cartridges and 2 consoles from existing ITL stock (not incremental to Memphasys)

Within the ITL agreement

Early. About 75,000 ART cycles a year; 165 centres targeted

Vietnam

Registered Aug 2026; 600-cartridge commercial order triggered (700 in total)

About A$530.2k over 2 years

Accelerating

Thailand

Thai FDA approval activated the 3-year agreement; 200 cartridges and 6 paid consoles

About A$430.5k over 3 years

Accelerating

India

Awaiting CDSCO approval, which was expected in the Sep 2026 quarter.

About A$98.8k in year 1, rising to about A$148k in year 2

Pending

Japan

Repeat use through Vitrolife Japan KK. Reimbursement hurdle limits the addressable market to the about 20% unreimbursed private segment

—

Stagnant/declining after FY2024. Revenue fell to A$3.7k in FY2025, pending trial data and reimbursement

Canada / New Zealand

Vitrolife 5-year agreements (Jan 2024); training and evaluation only

—

Dormant

“—” = not publicly disclosed.

Share Price and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Share price at start of FY (AUD)

0.0640.0400.0140.0070.004

Share price at end of FY (AUD)

0.0400.0140.0070.0040.007

FY share price change (%)

-37.5-65.0-50.0-42.975.0

Basic EPS (AUD)

-0.0027-0.0018-0.0023-0.0015-0.0016

Share Price & Returns

HorizonReference start priceApproximate change

1-year (late Oct 2025, A$0.004 at 31 Oct 2025)

0.004+38%

3-year (30 Jun 2023 close as proxy)

0.014-61%

5-year (1 Jul 2021 as proxy)

0.064-91%

Valuation Snapshot

MetricValueBasis

Market capitalisation

About A$17.0m

3,095.2m shares (incl. 8m to Chapter One) × A$0.0055

Enterprise value

About A$20.1m

Market cap + A$4.24m note − A$1.18m cash (30 Jun 2026). Excludes the A$1.06m ATO liability

EV / Sales FY2026

About 73x

EV / A$0.274m

EV / contracted minimums

About 4.8x

EV / A$4.2m multi-year minimums (not annual)

P/E

Not meaningful (loss-making)

—

EV / EBITDA

Not meaningful (negative EBITDA)

—

P/B

About 4.0x

A$17.0m / A$4.21m equity

Price / tangible book

Not meaningful (negative NTA)

—

Fully diluted shares (company)

About 5.62bn

Shares + options + note conversion at A$0.0024 (Sep 2026 presentation)

Capital Markets

ItemStatus

Sell-side coverage / consensus

None identified (not publicly disclosed)

Dividend history and policy

No dividends paid; none recommended (FY2026). No dividend policy

Credit ratings (Moody's / S&P / Fitch)

Not rated

Share Price & Returns by Date

DateTypeShares (m)Price (AUD)Proceeds (AUD K)

1 Oct 2025

Placement

257.50.003772.5

10 Nov 2025

Rights issue shortfall

180.50.003541.4

11 Nov 2025

Tranche 2 placement (incl. director)

33.30.003100.0

19 Dec 2025

Shares in lieu of director fees

6.60.00319.8

30 Dec 2025

Placement

193.10.003579.2

31 Dec 2025

Shares for services

26.00.00378.0

16 Feb 2026

Placement

160.00.005800.0

26 Jun 2026

Placement

240.00.0051,200.0

Capital Instruments

InstrumentLenderFace / carrying (AUD K)RateMaturitySecurityConversion

Convertible notes

Peters Investments Pty Ltd (13.19% holder as last disclosed)

4,135.8 face; 4,244.1 carrying incl. accrued interest

8% (interest and fees also accrue interest)

30 Jun 2027

Unsecured

A$0.0024 per share (Sep 2026 presentation)

Third-party secured loan (R&D refund-backed)

Third party

0 (repaid in FY2026; 638.3 at FY2025)

15%

Repaid

R&D refund

—

Metric

FY2027

FY2028

FY2029

———

Scheduled debt maturities (AUD K)

4,244.100———

Analyst Conclusions

Management guidance and outlook (Jun 2026 quarterly; FY2026 AR; Sep 2026 presentation)

  • September 2026 quarter sales expected to be "significantly higher again" than the June quarter (A$150k). Drivers: Monash rollout, Turkey, Vietnam and Thailand activations, ITL repeat orders, UK conversions.

  • Priorities: finish the Monash 2-site pilot and move to the 22-clinic national rollout; convert UK trials to contracts; secure Indian CDSCO approval; support Vietnam and Thailand launches; grow MENA and European utilisation; reduce COGS and expand margins.

  • Funding: cash runway of 2.8 quarters at 30 Jun 2026. Continued reliance on Lynx-supported placements. Options for the Peters note (repay, restructure or convert) to be considered before 30 Jun 2027.

  • Formal revenue or EBITDA guidance: not provided.

Consensus

No sell-side consensus exists. Analyst framework (derived, illustrative only): if all A$4.2m+ of announced minimums were delivered evenly over an average 3–4 year term, contracted revenue would be about A$1.1–1.4m a year. That is roughly 4–5x FY2026 revenue, before any Monash volumes, but still well below the annual cash cost base of about A$3–3.5m. Cash break-even needs either much higher utilisation (Monash national rollout plus Europe) or gross margins approaching the 60% target.

Bull case

  1. Evidence plus approvals equals adoption. RCT-grade superiority over DGC (p=0.022), combined with CE, TGA, MHRA and Asian registrations, gives Felix a credible clinical and regulatory moat. The MENA ramp (1,800 cartridges in about two quarters) shows that distributor minimums can turn into orders quickly.

  2. The Monash rollout is a step change. A move to 22 clinics and about 12,000 stimulated cycles a year would make Australia a reference market. Even 25% Felix penetration at A$100 per cartridge implies about A$0.3m a year from Monash alone, more than all FY2026 revenue (derived).

  3. Operating leverage and optionality. Burn has fallen to about A$140–250k a month. Revenue growth from 11 agreements, a 60%+ gross-margin target, paused pipeline assets that could be partnered (RoXsta, AI-Port), and a A$17m market cap leave room for a re-rating or strategic acquisition by an IVF consumables major.

Bear case

  1. Funding and dilution spiral. Negative working capital (-A$4.8m), negative NTA, a going-concern uncertainty and a A$4.2m note due Jun 2027. Further placements at 0.3–0.5¢ and note conversion (about 1.75bn shares) could dilute existing holders heavily and give Peters effective control.

  2. Unit economics are unproven. Gross margin was about 0% in FY2026. Cartridges at A$80–150 compete with near-zero-cost gradient media and swim-up, with no reimbursement. Distributor price points of about A$65 implied under the ITL minimums leave little margin unless COGS falls sharply.

  3. Governance and execution capacity. No CEO or CFO, a 3-person board with two related-party commercial relationships, dissolved committees, a FY2024 restatement and inconsistent share data. Managing 11 international partners with this structure carries high execution risk.

Catalysts and monitorables (next 12 months)

TimingCatalyst / monitorableWhat to watch
Oct 2026Sep 2026 quarterly / Appendix 4CRevenue vs A$150k; cash receipts (Jun-quarter receivables); burn; cash balance
Q4 CY2026Monash pilot completion and national rolloutFormal trigger of the 12-month term; number of active clinics
Q4 CY2026India CDSCO approvalActivation of the Andro Diagnostics minimums
25 Nov 2026AGMBoard renewal; capital approvals; CEO appointment
5 Nov 2026Expiry of about 470m options at 1.1¢Overhang falls unless the share price rises above 1.1¢
Dec 2026 quarterFirst Poland minimum order; Nordic and INVIDO ordersConversion of European distributors
H1 CY2027UK contract conversionsRecurring UK cartridge orders
By 30 Jun 2027Peters Investments note resolutionRepayment, extension, restructure or conversion
OngoingGross margin and COGSProgress towards 60%+
OngoingPeer-reviewed publication of the Monash pivotal trialIndependent validation for KOLs

Analyst verdict

Memphasys is at a real but fragile inflection point. After nearly 20 years as a separation-science company that never generated meaningful revenue, it has done three hard things in 18 months. It produced randomised multi-centre evidence that Felix beats density-gradient centrifugation on embryo utilisation. It secured a CE Mark under the demanding EU MDR, followed quickly by TGA, MHRA and several Asian and Turkish registrations. And it signed 11 commercial agreements with more than A$4.2m of announced minimums, including an exclusive national arrangement with Monash IVF. FY2026 revenue rose from A$3.7k to A$274k, with record June-quarter revenue of A$150k. These are not trivial achievements for a company valued at about A$17m.

The financial position, however, leaves almost no room for error. Gross margin was effectively zero in FY2026. Working capital is negative A$4.8m, net tangible assets are negative, and the auditor flagged a material going-concern uncertainty. A A$4.2m convertible note, convertible at a fraction of a cent, matures in June 2027. The company has no CEO or CFO. Its three-person board includes two directors with paid commercial relationships, and its audit committee has been dissolved. The share count has more than doubled in two years, and more dilution is likely.

On balance, Memphasys is a high-risk, binary, speculative situation. The commercial thesis is now evidence-based and its contractual footprint is unusually broad for its size. Equity value, however, depends on three things happening within about 12 months: the Monash rollout reaching national scale, cartridge COGS falling enough to produce the targeted gross margins, and the Peters note being resolved without a disorderly change of control.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleAppointedBackgroundEducationHoldings (30 Jun 2026)

David Tasker

Non-Executive Chair (described as independent)

19 May 2026

MD and co-founder of Chapter One Advisors (Perth IR/media firm); 13+ years as National Director IR at PPR; IR adviser to Memphasys for 7+ years

BCom (Marketing & Management), Murdoch University

51,102,070 shares (indirect); 15,666,666 options

Marjan Mikel

Non-Executive Director; Chair, Commercialisation Committee

19 Jun 2025

CEO and MD of Vitasora Health (ASX: VHL); founding MD of Healthy Sleep Solutions (ResMed cornerstone, sold to Air Liquide); MSD, Pharmacia, IMS Health

MCom; BSc (Hons); Grad Dip Ed; MAICD

15,838,792 shares; 26,666,667 options

Mathew Watkins

Independent Non-Executive Director

20 Oct 2025

Chartered Accountant; Australia Market Lead at Vistra; company secretary to several ASX entities

BBus; CA

Nil

Board of Directors — Dr Lindley Edwards

NameRoleDepartureNotes

Dr Lindley Edwards

Non-Executive Chair

Resigned 18 May 2026

CEO, AFG Venture Group. AFG was paid A$80,673 for advisory services

Dr David Ali

Executive Director and CEO

Left board 20 Oct 2025; ceased as CEO 31 Dec 2025

BSc, PhD (Macquarie); 40+ years in reproductive pharma/devices

Paul Wright

Independent NED

Resigned 10 Sep 2025

NED of Hydrix Ltd

Michael Atkins

Independent NED

Resigned 25 Jul 2025

NED of SRG Global

Board of Directors — A/Prof Hassan Bakos

NameTitleNotes

A/Prof Hassan Bakos

Director – Clinical Engagement & Growth (formerly Director of Operations)

20+ years in ART leadership. Base salary A$250,000 plus super; STI up to 20%, LTI up to 25%

Laureate Prof John Aitken

Scientific Director

Architect of the Felix science. Ceased to be KMP from 1 Jul 2026

Dr Tony Poulton

Key Account Manager, ANZ

20+ years at Cardinal Health and Covidien. Leads the Monash rollout

Stefan Ross

Company Secretary (from 8 Oct 2025)

Vistra; replaced Andrew Metcalfe

CEO / CFO

Vacant / not publicly disclosed

No CEO since 31 Dec 2025. Director of Finance Pablo Neyertz resigned 14 Nov 2025

Directors' Remuneration

NameCash salary and feesSTISuperLong service leaveOptions (SBP)Total

Lindley Edwards

82,21209,8650092,077

Paul Wright

6,67600006,676

Michael Atkins

2,21400002,214

Marjan Mikel

168,53000028,005196,535

Mathew Watkins

34,949000034,949

David Tasker

9,37500035,06444,439

David Ali

288,531029,70000318,231

Pablo Neyertz (incl. A$40,384 termination)

168,420011,55000179,970

Hassan Bakos

250,000030,0005,81313,710299,523

Total KMP

1,010,907081,1155,81376,7791,174,614

Major Shareholders

HolderShares% (as last disclosed)Indicative % of 3,087.2m shares (derived)Source

Peters Investments Pty Ltd (also convertible noteholder)

261,564,79113.198.47

Substantial holder data (InvestSMART)

Andrew Goodall

—

Described as second-largest shareholder (Aug 2024)

—

FY2024 Appendix 4E

Alison Coutts (former MD)

88,707,336

6.49 (Nov 2023)

—

MarketScreener

David Tasker (Chair)

51,102,070—1.66

FY2026 AR

Marjan Mikel

15,838,792—0.51

FY2026 AR

Lindley Edwards (former)

5,848,840—0.19

FY2026 AR

“—” = not publicly disclosed.

Competitive Landscape

Key Competitors

#Competitor / productCompanyApproachPositioning vs Felix
1

Density gradient media (e.g., SpermGrad)

Vitrolife Group (Sweden)

DGC (centrifugation)

The incumbent standard. Very low cost per sample; globally entrenched. Ironically, Vitrolife is also Memphasys' distributor in Japan, Canada and NZ

2

Isolate and sperm-washing media

FUJIFILM Irvine Scientific

DGC media

Incumbent; broad IVF media portfolio

3

PureSperm

Nidacon International

DGC media

Incumbent

4

ORIGIO gradient media; PICSI hyaluronan-binding dish

CooperSurgical (Cooper Companies)

DGC; hyaluronan-binding selection

Global IVF consumables leader with bundled portfolio

5

ZyMōt microfluidic sperm separation device

ZyMōt Fertility (DxNow)

Microfluidic, centrifuge-free

Closest functional substitute. Centrifuge-free, low DNA fragmentation, no capital console

6

Fertile chip (microfluidic)

Koek Biotechnology

Microfluidic

Low-cost chip; direct alternative

7

LensHooke sperm separation device

Bonraybio

Microfluidic/filtration

Lower-cost alternative

8

MACS ART Annexin V

Miltenyi Biotec

Magnetic-activated cell sorting (removes apoptotic sperm)

Adjunct for high-DNA-fragmentation cases

9

Swim-up (method, no vendor)

—

Migration

Free method; Felix trial showed non-inferiority

10

IMSI / high-magnification selection

Various microscope OEMs

Morphological selection

Adjacent, labour-intensive

11

Lab automation and equipment players

Hamilton Thorne and others

Analysis and lab equipment

Potential entrants or partners in automation

Peer Comparison FY2026

MetricMemphasys (FY2026)ZyMōt Fertility

Revenue

A$0.27m

Private; not disclosed

Revenue growth

+7,300% (from A$3.7k)

—

Gross margin

About 0.1%

—

EBITDA margin

About -1,130%

—

R&D intensity (total R&D / revenue)

About 358%

—

Regulatory

CE (MDR), TGA, MHRA, VN, TH, TR

FDA-cleared; CE

“—” = not publicly disclosed.

Recent Developments

The company states it is "free of any litigation claims" (FY2026 AR).

Company Snapshot

$0.2M

Revenue

28

Employees

2006

Founded

Homebush West, Australia

Headquarters

SWOT Analysis

Strengths

  • Positive randomised pivotal data: embryo utilisation 58.8% vs 49.1% for DGC (p=0.022), across 103 couples in 10 Monash centres; non-inferior to swim-up (Sep 2026 presentation).
  • Regulatory breadth for a micro-cap: CE Mark under EU MDR (29 Dec 2025), TGA (9 Feb 2026, about two months ahead of guidance), MHRA, Vietnam, Thailand and Turkey. Six clearances or registrations in total.
  • Contracted demand: 11 public agreements with A$4.2m+ in announced minimums across 31+ countries (Sep 2026 presentation), compared with FY2026 revenue of A$274k.
  • Demonstrated pull-through in MENA: 1,800 of the 2,500-cartridge annual minimum ordered within two quarters; HMC ordered a second console (Jun 2026 quarterly).
  • Anchor customer: Monash IVF national exclusive covering 22 clinics, about 21% of Australian stimulated IVF (16 Jun 2026).
  • Cost reduction: quarterly operating cash outflows down 71%, from A$1.441m (Dec 2025 quarter) to A$422k (Jun 2026 quarter).
  • Scientific pedigree: Laureate Prof. John Aitken and the University of Newcastle partnership; 14+ granted patents.

Weaknesses

  • Immaterial revenue relative to costs: FY2026 revenue A$274k against total expenses of A$4.81m.
  • Zero gross margin: direct costs A$273.5k against revenue A$273.8k (FY2026).
  • Balance-sheet fragility: working-capital deficit of A$4.81m; negative net tangible assets; going-concern material uncertainty (BDO, FY2026).
  • No CEO or CFO since Dec 2025 / Nov 2025. The board-led model has a 3-person board and dissolved committees.
  • Related-party concentration: Chair's IR firm (A$120k) and a director's consultancy (A$184k) were paid in FY2026; total related-party services A$384.8k, about 140% of revenue.
  • Heavy dilution: shares grew from 1,382.7m to 3,087.2m between Jun 2024 and Jun 2026; 779m options outstanding; note convertible into about 1.75bn shares at A$0.0024.
  • Weak financial reporting quality signals: FY2024 restatement (A$929k); unreconciled weighted-average share counts; two EBITDA definitions in the same report; a minor typo in the equity statement (accumulated losses shown as A$60,377,498 against A$60,377,496).

Opportunities

  • Monash national rollout to 22 clinics after the 3-month pilot. That network performs about 12,000 stimulated cycles a year.
  • India CDSCO approval would activate the Andro Diagnostics agreement (200+ clinic network; 450 cartridges a quarter).
  • Europe: UK trials could convert to contracts, and new distributors in Poland, the Nordics and Central Europe (€526.5k Nordic minimum; about A$674k INVIDO).
  • COGS reduction towards the 60%+ gross-margin target at A$80–150 per cartridge.
  • Platform optionality: RoXsta (human and bovine oxidative-stress testing) and AI-Port (livestock) could be partnered or out-licensed without spending Memphasys' own capital.
  • Strategic interest from IVF consumables majors. Vitrolife is already a distributor. Microcap valuations in med-tech often attract acquirers once a product has regulatory approval (speculative; no deal rumoured).

Threats

  • Refinancing and control risk around the A$4.2m Peters note due 30 Jun 2027. Conversion would hand Peters a large, potentially controlling stake.
  • Microfluidic substitutes (ZyMōt, Fertile chip, LensHooke) with no console cost.
  • Distributor under-performance. Minimums depend on partners' sales capability (FY2026 AR risk 4).
  • Reimbursement and pricing pressure (FY2026 AR risk 13; Japan precedent).
  • Funding-market risk: placements at 0.3–0.5¢; cash runway of 2.8 quarters at 30 Jun 2026.
  • Single-product concentration: all value rests on Felix, and other projects may lose viability (FY2026 AR risk 2).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
19 Jun 2025Marjan Mikel appointed NEDBrings med-tech commercial and regulatory experience. Later chairs the Commercialisation Committee
25 Jul 2025Michael Atkins resigns as NED and Audit & Risk Committee chairStart of board turnover
29 Aug 2025FY2025 results: revenue A$3.7k; loss A$5.04m; A$896k impairmentLowest point for revenue
8 Sep 2025ITL 5-year exclusive MENA agreementFirst large distributor minimum (A$390k)
10 Sep 2025Paul Wright resignsBoard turnover
18 Sep 2025ITL agreement expanded to TurkeyAdds a market of about 75k cycles a year
1 Oct 2025Placement of 257.5m shares at 0.3¢ (A$772.5k)Emergency funding. Cash had fallen to A$4k at 30 Sep 2025
8 Oct 2025Stefan Ross (Vistra) appointed Company SecretaryOutsourced governance
20 Oct 2025Mathew Watkins appointed; Dr Ali leaves boardBoard refresh
28 Oct 2025India agreement with Andrology Center Coimbatore / Andro DiagnosticsIndia pathway, subject to CDSCO approval
31 Oct 2025Sep 2025 quarterly: operating outflow A$451k; A$0.84m placement plus A$1.12m rights issueLiquidity stress made public
10 Nov 2025Rights issue shortfall placed (180.5m shares; A$541k)Funding
14 Nov 2025Director of Finance Pablo Neyertz resignsFinance leadership gap
20 Nov 2025AGM: pure-play Felix strategyStrategic reset
8 Dec 2025Direct-sales "match-ready" programme; ASPIRE keynote by A/Prof BakosPre-launch demand creation
18 Dec 2025ITL places a 500-cartridge order ahead of CE MarkFirst signal of distributor demand
22 Dec 2025CFA Italia 5-year agreement (about A$925k) with 500-cartridge initial orderEU anchor customer
29 Dec 2025CE Mark under EU MDRMain regulatory de-risking event
30 Dec 2025Placement of 193.1m shares (A$579k)Funding
31 Dec 2025Dr Ali ceases as CEOBoard-led model begins
Jan 2026Board committees dissolvedGovernance weakened
2 Feb 2026HMC (Qatar) commitment; MENA clinic demandInstitutional adoption
3 Feb 2026TGA submission and UK MHRA pathwayRegulatory progress
9 Feb 2026TGA/ARTG approval, ahead of guidanceOpens the home market
16 Feb 2026A$0.8m placement at 0.5¢Funding at a higher price
27 Feb 20261H FY2026 results: loss A$2.34m (pcp A$2.97m); revenue A$12.4k; burn guidance about A$250k a monthCost reset
7–8 Apr 2026Investor webinar and presentation (Mikel)Recurring-revenue narrative
17 Apr 2026Mar 2026 quarterly: first meaningful revenue (about A$112k)Commercial inflection
18–19 May 2026Edwards resigns; Tasker becomes ChairIR-led chair; related-party question
27 May 2026ITL 1,000-cartridge order; HMC second consoleCumulative 1,800 cartridges
1 Jun 2026TMSC Vietnam 2-year exclusive (about A$530k)Southeast Asia entry
16 Jun 2026Monash IVF 12-month exclusive national agreementLargest contract
17 Jun 2026Peters Investments convertible note extended to 30 Jun 2027Removes a near-term maturity cliff
18–26 Jun 2026A$1.2m placement (240m shares at 0.5¢)Funds inventory build
25 Jun 2026UK accelerated entry: four IVF groups trialling Felix; initial ordersUK beachhead
Jun–Jul 2026ESHRE 2026 (London) boothEuropean pipeline
1 Jul 2026IVF Envimed Thailand 3-year exclusive (about A$430.5k)Southeast Asia
15 Jul 2026Consulting agreement with a director announcedRelated-party governance
16 Jul 2026Jun 2026 quarterly: record A$150k revenue; cash A$1.179m; 2.8 quarters of fundingMomentum
22 Jul 20268m shares proposed to Chapter One Advisors for servicesRelated-party equity
5 Aug 2026TK Biotech Poland exclusive agreementEU expansion
9–10 Aug 2026Pivotal Felix data presented at FSANZ 2026 (Canberra)Scientific validation
20 Aug 2026Vietnam registration achieved; later 600-cartridge orderActivates TMSC agreement
28 Aug 202631.25m options expireOverhang reduces slightly
Late Aug / early Sep 2026Turkey ÜTS registration; first sale of 100 cartridges and 2 consoles; Thai FDA approval activates Envimed agreementMarket activations
31 Aug 2026FY2026 audited results; going-concern material uncertainty–
1 Sep 2026NOVIVITAE Nordic agreement (€526,500)9 European countries
8 Sep 2026Investor webinar; A$4.2m+ contracted minimums; 11 agreements; 31+ countriesUpdated investment case
18 Sep 2026INVIDO LAB agreement (about A$674k)Central Europe
25 Nov 2026 (scheduled)AGMBoard elections; possible capital approvals

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

5 charts
Income Statement: Revenue & Gross Profit: Revenue rose from AUD 0 Mn in FY2022 to AUD 0.3 Mn in FY2026.
Memphasys Ltd — Income Statement: Revenue & Gross Profit
Series (AUD Mn)FY2022FY2023FY2024FY2025FY2026
Revenue000.100.3
Gross profit—00-00

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Memphasys Limited, Appendix 4E and audited Consolidated Financial Statements, year ended 30 June 2026 (31 Aug 2026) (investorpa.com)
  2. Memphasys, Quarterly Activities Report and Appendix 4C, quarter ended 30 June 2026 (16 Jul 2026) (announcements.asx.com.au)
  3. Memphasys, Investor Presentation, September 2026 (8 Sep 2026) (bulletin.webull.com)
  4. Memphasys, Appendix 4E, year ended 30 June 2024 (30 Aug 2024) (announcements.asx.com.au)
  5. Memphasys, Appendix 4E, year ended 30 June 2025 (29 Aug 2025) (announcements.asx.com.au)
  6. Memphasys, Half-year report summary to 31 Dec 2025 (27 Feb 2026) (investorpa.com)
  7. Memphasys, Quarterly Report, period ended 31 March 2026 (17 Apr 2026) (announcements.asx.com.au)
  8. Memphasys, Investor Webinar and Presentation (7 Apr 2026) (bulletin.webull.com)
  9. Memphasys, CE Mark approval (29 Dec 2025) (announcements.asx.com.au)
  10. Memphasys, CFA Italia agreement (22 Dec 2025) (announcements.asx.com.au)
  11. Memphasys, ITL pre-CE order (18 Dec 2025) (announcements.asx.com.au)
  12. Memphasys, Direct sales update (8 Dec 2025) (announcements.asx.com.au)
  13. Memphasys, HMC commitment (2 Feb 2026) (announcements.asx.com.au)
  14. Memphasys, TGA submission / UK pathway (3 Feb 2026) (announcements.asx.com.au)
  15. Memphasys, TGA approval (9 Feb 2026) (announcements.asx.com.au)
  16. Memphasys, Investor presentation "Anchored by Monash IVF" (24 Jun 2026) (investorpa.com)
  17. Memphasys, Poland agreement (5 Aug 2026) (announcements.asx.com.au)
  18. Memphasys, Vietnam registration (20 Aug 2026) (announcements.asx.com.au)
  19. Memphasys, Nordic agreement (1 Sep 2026) (announcements.asx.com.au)
  20. Memphasys, INVIDO LAB agreement (18 Sep 2026) (investorpa.com)
  21. Grafa, "Memphasys secures Turkish registration and initial sales" (grafa.com)
  22. StockWireX, FSANZ 2026 Felix study summary (stockwirex.com)
  23. NuSep AGM presentation (21 Nov 2007) (announcements.asx.com.au)
  24. NuSep release on Gels offer (23 Jun 2008) and 2012 placement (financialfilings.com) · financialfilings.com
  25. Market Index, MEM corporate details (listing date, former names, auditor) (marketindex.com.au)
  26. InvestSMART, MEM share price and substantial holders (investsmart.com.au)
  27. InvestSMART, Sep 2025 quarterly summary (investsmart.com.au)
  28. Morningstar Australia, MEM profile (morningstar.com.au)
  29. MarketScreener, Alison Coutts insider profile (NuSep Inc. divestiture) (zonebourse.com)
  30. Yahoo Finance, MEM.AX quote and profile (finance.yahoo.com)
  31. Financialfilings.com, Memphasys issuer data (LEI) (financialfilings.com)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.